Literature DB >> 2254107

Combined therapy of localized Ewing's sarcoma of bone: analysis of results in 100 patients.

E Barbieri1, E Emiliani, G Zini, A Mancini, A Toni, G Frezza, S Neri, C Putti, L Babini.   

Abstract

From 1979 to 1986, 182 patients with biopsy proven diagnosis of Ewing's sarcoma of bone were observed. One hundred of the 182 patients (72 males, 28 females, median age 15.8 years) with localized disease and no previous treatment were treated with chemotherapy (VCR, ADM, CTX, D-ACT) for 15-18 months. Local treatment was radiotherapy (42 patients), surgery (31 patients), or a combination of both (27 pts). Radiation doses ranged from 45 to 64 Gy given with conventional fractionation. Median follow-up was 51.2 months (24-106). Overall and disease-free survival were, respectively, 58.7 and 42.6%. Resected patients tended to have a better local control (Surgery 93.6%, Surgery + Radiation therapy 92.6%, Radiation therapy 69.1%). Disease-free survival was significantly related to the volume of the primary tumor (bulky: 33.2%, not-bulky: 57.7%), to site (extremities 54.6%, central sites 16.6%, other sites 40.9%), and to local treatment (Radiation therapy 30.3%, Surgery + Radiation therapy 47.9%, Surgery 59.1%). These results are, however, biased because resected patients tended to have smaller tumors in favorable sites.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2254107     DOI: 10.1016/0360-3016(90)90223-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Metastatic extraosseous Ewing's sarcoma (EES)/primitive neuroectodermal tumor (PNET) of the kidney: 8-year durable response after induction and maintenance chemotherapy.

Authors:  Stephen L Richey; Priya Rao; Christopher G Wood; Shreyaskumar Patel; Nizar M Tannir
Journal:  Clin Genitourin Cancer       Date:  2012-04-13       Impact factor: 2.872

Review 2.  Management of infection following reconstruction in bone tumors.

Authors:  Sudhir K Kapoor; Rajesh Thiyam
Journal:  J Clin Orthop Trauma       Date:  2015-07-07

3.  Classification of histopathologic changes following chemotherapy in Ewing's sarcoma of bone.

Authors:  H J van der Woude; J L Bloem; A H Taminiau; M A Nooy; P C Hogendoorn
Journal:  Skeletal Radiol       Date:  1994-10       Impact factor: 2.199

4.  Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.

Authors:  Linda Granowetter; Richard Womer; Meenakshi Devidas; Mark Krailo; Chenguang Wang; Mark Bernstein; Neyssa Marina; Patrick Leavey; Mark Gebhardt; John Healey; Robert Cooper Shamberger; Allen Goorin; James Miser; James Meyer; Carola A S Arndt; Scott Sailer; Karen Marcus; Elizabeth Perlman; Paul Dickman; Holcombe E Grier
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

5.  Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study).

Authors:  O Oberlin; M C Deley; B N Bui; J C Gentet; T Philip; P Terrier; C Carrie; F Mechinaud; C Schmitt; A Babin-Boillettot; J Michon
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

6.  The Impact of Radiotherapy Dose on Local Control of Ewing's Sarcoma of Bone.

Authors:  N G Burnet; J M Bliss; C L Harmer
Journal:  Sarcoma       Date:  1997
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.